Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases

Journal of the National Cancer Institute

Volumn 91, Issue 20, 1999, Pages 1744-1750

  Gnant, Michael F X ^a   Noll, Linda A ^c   Irvine, Kari R ^c   Puhlmann, Markus ^c   Terrill, Richard E ^c   Alexander Jr , H Richard ^c   Bartlett, David L ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; THYMIDINE KINASE; VIRUS ANTIBODY; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; FEMALE; GENE TARGETING; IMMUNE SYSTEM; LIVER METASTASIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPORTER GENE; TRANSGENE; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 0033589344     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.20.1744     Document Type: Article

References (39)

1. Moss B. Vaccinia virus. A tool for research and vaccine development. Science 1991;252: 1662-7.
2. Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, et al. Vaccinia as a vector for tumor directed gene therapy: biodistribution of a thymidine kinase deleted mutant. Cancer Gene Therapy. In press 1999.
3. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985;317:813-5.
4. Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 1999;10: 649-57.
5. Kidd JG, Rous P. A transplantable rabbit carcinoma originating in a virus-induced papilloma and containing the virus in masked or altered form. J Exp Med 1940;71:813-37.
6. Swistel AJ, Bading JR, Raaf JH. Intraarterial versus intravenous adriamycin in the rabbit Vx-2 tumor system. Cancer 1984;53: 1397-404.
7. Davison AJ, Moss B. Structure of vaccinia virus early promoters. J Mol Biol 1989;210: 749-69.
8. Davison AJ, Moss B. Structure of vaccinia virus late promoters. J Mol Biol 1989;210: 771-84.
9. Earl PL, Moss B. Expression of proteins in mammalian cells using vaccinia viral vectors. In: Ausubel FM, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, editors. Current protocols in molecular biology. New York (NY): Greene/Wiley Interscience; 1991. p. 16.15.1-16.18.10.
10. Shu SY, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res 1985;45:1657-62.
11. Wilkinson GW, Borysiewicz LK. Gene therapy and viral vaccination: the interface. Br Med Bull 1995;51:205-16.
12. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther 1994;1:51-64.
13. Zhang J, Russell SJ. Vectors for cancer gene therapy. Cancer Metastasis Rev 1996;15: 385-401.
14. Oshiro EM, Viola JJ, Oldfield EH, Walbridge S, Bacher J, Frank JA, et al. Toxicity studies and distribution dynamics of retroviral vectors following intrathecal administration of retroviral vector-producer cells. Cancer Gene Ther 1995;2:87-95.
15. Rous P, Beard JW. The progression to carcinoma of virus-induced rabbit papillomas (SHOPE). J Exp Med 1935;62:523-48.
16. Baba N, Haam E von. Animal model: spontaneous adenocarcinoma in aged rabbits. Am J Pathol 1972;68:653-6.
17. Aigner KR, Link KH, Woescher H, Johannes W, Hundeiker M. Regional perfusion of VX 2 carcinoma with cis-DDP. Anticancer Res 1983;3:431-4.
18. Wagner S. Benign lymph node hyperplasia and lymph node metastases in rabbits. Animal models for magnetic resonance lymphography. Invest Radiol 1994;29:364-71.
19. Kunieda K, Seki T, Nakatani S, Wakabayashi M, Shiro T, Inoue K, et al. Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer. Br J Cancer 1993;67:668-73.
20. Cheng SQ, Zhou XD, Tang ZY, Yu Y, Wang HZ, Bao SS, et al. High-intensity focused ultrasound in the treatment of experimental liver tumour. J Cancer Res Clin Oncol 1997;123: 219-23.
21. Prat F, Centarti M, Sibille A, Abou el Fadil FA, Henry L, Chapelon JY, et al. Extracorporeal high-intensity focused ultrasound for VX2 liver tumors in the rabbit. Hepatology 1995;21: 832-6.
22. Nishizaki T, Matsumata T, Kanematsu T, Yasunaga C, Sugimachi K. Surgical manipulation of VX2 carcinoma in the rabbit liver evokes enhancement of metastasis. J Surg Res 1990; 49:92-7.
23. Butler JA, Trezona TP, Nordestgaard A, State D. Hepatic artery versus portal vein and systemic infusion of fluorodeoxyuridine of rabbit VX-2 hepatic implants. Am J Surg 1989;157: 126-9.
24. Curley SA, Stone DL, Fuhrman GM, Hohn DC, Siddik ZH, Newman RA. Increased doxorubicin levels in hepatic tumors with reduced systemic drug exposure achieved with complete hepatic venous isolation and extracorporeal chemofiltration. Cancer Chemother Pharmacol 1993;33:251-7.
25. 2 cancer injected into rabbit liver. Cancer Res 1986;46:4167-70.
26. Tanaka H, Taniguchi H, Mugitani T, Koishi Y, Masuyama M, Higashida T, et al. Intra-arterial administration of the angiogenesis inhibitor TNP-470 blocks liver metastasis in a rabbit model. Br J Cancer 1995;72:650-3.
27. Singhal S, Kaiser LR. Cancer chemotherapy using suicide genes. Surg Oncol Clin N Am 1998;7:505-36.
28. Brand K, Arnold W, Bartels T, Lieber A, Kay MA, Strauss M, et al. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther 1997;4:9-16.
29. Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1β. Ann Surg Oncol 1995;2:151-9.
30. Peplinski GR, Tsung K, Meko JB, Norton JA. In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta. Surgery 1995;118: 185-90; discussion 190-1.
31. Peplinski GR, Tsung K, Norton JA. Vaccinia virus for human gene therapy. Surg Oncol Clin N Am 1998;7:575-88.
32. Gnant MF, Puhlmann M, Alexander HR Jr, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res 1999;59:3396-403.
33. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 1996;93: 11341-8.
34. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A 1996;93:11349-53.
35. Kim CJ, Cormier J, Roden M, Gritz L, Mazzara GP, Fetsch P, et al. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann Surg Oncol 1998;5:64-76.
36. Fenner F, Henderson DA, Aritz I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva (Switzerland): World Health Organization; 1988.
37. Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, et al. Safety of an immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991;337: 567-72.
38. McAneny D, Ryan CA, Beazley RM, Kaufman HL. Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 1996;3:495-500.
39. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997;89: 1595-601.